Horizons ETFs Management (Canada) Inc. recently announced completion of its quarterly rebalance of the constituent holdings of the Horizons Marijuana Life Sciences Index ETF (“HMMJ”). Pre-clinical stage biopharmaceutical company InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) is one of 11 new holdings that have been added to HMMJ’s portfolio, which is the world’s first ETF offering direct exposure to North American-listed securities involved with marijuana bioengineering and production. “Cannabis has been one of the newest and fastest-growing asset classes of 2017, presently valued at approximately $23 billion,” Steve Hawkins, president and CEO of Horizons ETFs, stated in a news release. “The continued expansion of HMMJ’s Index and portfolio demonstrates how quickly this sector has evolved and why it should be considered a long-term, domestic investment opportunity for Canadian investors.”
Read the full article
Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer
Read More
InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) Added to Horizons Marijuana Life Sciences Index ETF
